Media release Basel, Switzerland, 22.05.2024 BaseLaunch announces a new partnership with AbbVie Further strengthens BaseLaunch’s global pharma industry partnerships 24 early-stage biotech ventures have now been supported by BaseLaunch Portfolio companies have raised over US$ 600 million in equity capital BaseLaunch, the Basel-based biotech venture incubator, today announces that AbbVie has become its newest partner. […]
Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire a majority stake in Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process. Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and […]
Proprietary E3 ligase platform to enable protein stabilisation “at source”, thereby restoring the body’s sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges of drugging these targets Pipeline of first-in-class, small molecule, E3 ligase inhibitors to stabilise proteins and treat disease in several therapeutic areas, including […]
Investment will support development of a differentiated pipeline in oncology Most advanced asset is D3S-001 with potential to be a best-in-class KRAS G12C inhibitor Data on lead asset D3S-001 to be presented at AACR on 8 April 2024 8 April 2024, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces an investment of […]
REDUCED, a Copenhagen-based company that uses fermentation technology to transform food and agriculture industry side streams into natural food ingredients, today announced it has secured EUR 6 million in new financing. The funds were raised from a range of investors, including new investment from Novo Holdings and the Nordic flavour house Einar Willumsen, as well […]
